Form 4: Recursion Pharmaceuticals Director Sells Shares Under 10b5-1 Plan

A Recursion Pharmaceuticals director, Blake Borgeson, sold 11,447 shares of Class A Common Stock at an average price of $7.6402 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on November 12, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $7.6402, with individual trades ranging from $7.48 to $8.01.
• Following the transaction, Borgeson beneficially owns 7,066,113 shares of Recursion Pharmaceuticals stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Risks

• Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 plans to manage their stock sales and avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate insiders to manage their stock sales.
• The reported transaction is similar to other Form 4 filings related to insider sales in publicly traded companies.
• The price range of $7.48 to $8.01 is within the typical trading range for the stock on the transaction date.

Stakeholder Impact

• The sale may have a minor impact on the stock price, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

Recursion Pharmaceuticals, insider trading, Form 4, 10b5-1 plan, stock sale, director, RXRX